CymitQuimica logo
BTK

BTK

Los inhibidores de la tirosina quinasa de Bruton (BTK) son compuestos que específicamente se dirigen e inhiben la BTK, una enzima crucial involucrada en la señalización del receptor de células B y en la regulación de la angiogénesis. La BTK desempeña un papel significativo en la proliferación y supervivencia de las células cancerosas, particularmente en las malignidades hematológicas. Al inhibir la BTK, estos compuestos pueden interrumpir la angiogénesis y el crecimiento tumoral, lo que los convierte en valiosos en la terapia contra el cáncer. En CymitQuimica, ofrecemos una gama de inhibidores de BTK de alta calidad para apoyar su investigación en oncología, inmunología y angiogénesis.

Se han encontrado 169 productos para "BTK".

Ordenar por

Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
productos por página.
  • SJF620 hydrochloride

    CAS:
    SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].
    Fórmula:C41H45ClN8O7
    Pureza:98%
    Forma y color:Solid
    Peso molecular:797.3

    Ref: TM-T74002

    5mg
    A consultar
    50mg
    A consultar
  • Ibrutinib dimer

    CAS:
    Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).
    Fórmula:C50H48N12O4
    Pureza:98%
    Forma y color:Solid
    Peso molecular:880.99

    Ref: TM-T11602

    100mg
    A consultar
    500mg
    A consultar
  • PCI-33380

    CAS:
    PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.
    Fórmula:C46H52BF2N11O3
    Pureza:98%
    Forma y color:Solid
    Peso molecular:855.8

    Ref: TM-T16441

    25mg
    897,00€
    50mg
    1.414,00€
  • Tyrosinase-IN-16

    CAS:
    Tyrosinase-IN-16 inhibited tyrosinase.
    Fórmula:C8H6BrN3S
    Pureza:99.94%
    Forma y color:White Solid
    Peso molecular:256.12

    Ref: TM-T67939

    25mg
    49,00€
    50mg
    66,00€
    100mg
    89,00€
    200mg
    130,00€
  • PROTAC BTK Degrader-12

    CAS:
    PROTAC BTK Degrader-12 (EXAMPLE 19) is a PROTAC-based BTK degrader, featuring a structure where the BTK ligand and linker are highlighted in pink and black, the linker in black, and the VHL ligand in blue.
    Fórmula:C47H54N12O4
    Forma y color:Solid
    Peso molecular:851.01

    Ref: TM-T204328

    10mg
    A consultar
    50mg
    A consultar
  • PROTAC BTK Degrader-10

    CAS:
    PROTAC BTK Degrader-10 (Example 1P) is a PROTAC compound that targets BTK for degradation. It is applicable in the research of chronic lymphocytic leukemia (CLL). [Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligase Cereblon].
    Fórmula:C42H49N11O4
    Forma y color:Solid
    Peso molecular:771.91

    Ref: TM-T204382

    10mg
    A consultar
    50mg
    A consultar
  • PROTAC BTK Degrader-9


    PROTACBTK Degrader-9 (compound 23) is a potent PROTACs degrader that specifically targets BTK. It effectively downregulates the RANKL-activated BTK-PLCγ2-Ca2+-NFATc1 signaling pathway. Consequently, PROTACBTK Degrader-9 inhibits osteoclastogenesis and reduces alveolar bone resorption in a mouse model of periodontitis.
    Fórmula:C46H52FN13O5
    Forma y color:Solid
    Peso molecular:885.41984

    Ref: TM-T209408

    10mg
    A consultar
    50mg
    A consultar
  • L18I


    L18I is a PROTAC (Proteolysis Targeting Chimera) that targets Btk to mitigate inflammation in autoimmune diseases. The components of L18I include the PROTAC target protein ligand IBT6A, the PROTAC linker Propargyl-PEG3-alcohol, and the E3 ubiquitin ligase ligand Lenalidomide-Br. Notably, the active control for the target protein ligand is IBT6A-CO-ethyne, while the conjugate of the E3 ubiquitin ligase ligand with the linker is Lenalidomide-C3-PEG3-N3.
    Fórmula:C47H51N11O8
    Forma y color:Solid
    Peso molecular:897.98

    Ref: TM-T200405

    10mg
    A consultar
    50mg
    A consultar
  • Ibrutinib-biotin

    CAS:
    Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).
    Fórmula:C56H80N12O9S
    Pureza:98%
    Forma y color:Solid
    Peso molecular:1097.39

    Ref: TM-T18049

    100mg
    A consultar
    500mg
    A consultar
  • GBD-9

    CAS:
    GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).
    Fórmula:C44H47N9O6
    Pureza:98%
    Forma y color:Solid
    Peso molecular:797.9

    Ref: TM-T79139

    5mg
    A consultar
    50mg
    A consultar
  • BTK inhibitor 19

    CAS:
    BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).
    Fórmula:C25H24F3N7O3
    Forma y color:Solid
    Peso molecular:527.508

    Ref: TM-T40185

    5mg
    873,00€
  • FDA-Approved Kinase Inhibitor Library


    A unique collection of xnum kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.
    Forma y color:Liquid

    Ref: TM-L1610

    1mg
    A consultar
    10μL*10mM (DMSO)
    A consultar
    20μL*10mM (DMSO)
    A consultar
    30μL*10mM (DMSO)
    A consultar
    50μL*10mM (DMSO)
    A consultar
    100μL*10mM (DMSO)
    A consultar
    250μL*10mM (DMSO)
    A consultar
  • PROTAC BTK Degrader-8


    PROTACBTK Degrader-8 (compound 3) is an efficient PROTAC BTK degrader with a linker that can couple with ADC antibodies to form PAC.
    Fórmula:C80H94F2N14O20P2
    Forma y color:Solid
    Peso molecular:1670.62121

    Ref: TM-T208958

    10mg
    A consultar
    50mg
    A consultar
  • LFM-A13

    CAS:
    LFM-A13 is a highly selective BTK inhibitor; IC50 2.5 uM; targets catalytic domain; severs BCR signaling; anti-leukemic; autoimmune disease and lymphocytic leukemia research.
    Fórmula:C11H8Br2N2O2
    Pureza:99.50%
    Forma y color:White Solid
    Peso molecular:360

    Ref: TM-T212732

    5mg
    52,00€
    10mg
    73,00€
    25mg
    105,00€
    50mg
    152,00€
  • BTK-IN-5

    CAS:
    BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,
    Fórmula:C23H32N4O5
    Forma y color:Solid
    Peso molecular:444.532

    Ref: TM-T39612

    5mg
    873,00€
  • PROTAC BTK Degrader-1

    CAS:
    Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.
    Fórmula:C43H43N9O4
    Forma y color:Solid
    Peso molecular:749.86

    Ref: TM-T74636

    5mg
    A consultar
    50mg
    A consultar
  • CNX-500

    CAS:
    CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.
    Fórmula:C48H68N10O9S
    Pureza:98%
    Forma y color:Solid
    Peso molecular:961.18

    Ref: TM-T10854

    5mg
    1.566,00€
    10mg
    2.602,00€
  • PROTAC BTK Degrader-2

    CAS:
    PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].
    Fórmula:C47H54F2N8O13
    Forma y color:Solid
    Peso molecular:976.97

    Ref: TM-T73868

    5mg
    A consultar
    50mg
    A consultar
  • BRK inhibitor P21d hydrochloride

    CAS:
    BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.
    Fórmula:C23H23ClFN7O2
    Forma y color:Solid
    Peso molecular:483.93

    Ref: TM-T39772

    25mg
    868,00€
  • PROTAC BTK Degrader-11

    CAS:
    PROTAC BTK Degrader-11 is a PROTAC degrader that targets and degrades BTK with a DC50 of 1.7 nM. It is utilized in oncological research.
    Fórmula:C48H55N11O4
    Forma y color:Solid
    Peso molecular:850.02

    Ref: TM-T201745

    10mg
    A consultar
    50mg
    A consultar